Antibiotic News and Research

RSS

Antibiotics are drugs used to treat infections caused by bacteria and other microorganisms.

UCSF, Anacor to discover and optimize novel oxaboroles as antimalarial drugs

Anacor Pharmaceuticals announced today that the University of California San Francisco (UCSF) has been awarded $718,136 in funding from the National Institutes of Health (NIH) to discover and optimize novel oxaboroles as antimalarial drugs in collaboration with Anacor Pharmaceuticals. The NIH grant provides support for the period beginning September 30, 2011 and ending September 29, 2012.

12 Oct 2011

New method employs Doppler ultrasound sensor to diagnose sinusitis

A new method of diagnosing sinusitis is presented in a new thesis from Lund University. The results offer the potential to reduce the use of antibiotics and the costs of the disease to society.

7 Oct 2011

Life Technologies, CHEO researcher partner to co-develop microbial detection tests

The Children's Hospital of Eastern Ontario (CHEO) Research Institute is pleased to announce that one of its principal investigators in infectious disease has signed a contract with Life Technologies, an internationally renowned biotech tools company headquartered in Carlsbad, California, to share information that will help to develop tests that uniquely amplify and detect the DNA coding for infectious diseases.

4 Oct 2011

Public health officials should determine community storage of anthrax-preventing antibiotics

As part of preparations for a possible large-scale anthrax attack, public health officials on the state and local levels should determine where and how anthrax-preventing antibiotics should be stored in their communities, says a new report from the Institute of Medicine.

1 Oct 2011

Roads may play a major role in the spread or containment of antibiotic resistant bacteria

Antibiotic resistant E. coli was much more prevalent in villages situated along roads than in rural villages located away from roads, which suggests that roads play a major role in the spread or containment of antibiotic resistant bacteria, commonly called superbugs, a new study finds.

30 Sep 2011

Positive new data from Otonomy's OTO-104 Phase 1b study on Meniere's disease

Otonomy, Inc., a clinical stage biopharmaceutical company developing innovative therapeutics for diseases and disorders of the inner and middle ear, today announced that researchers presented positive new data from a Phase 1b study of the company's lead product candidate, OTO-104, in patients with Meniere's disease.

29 Sep 2011

Cubist plans to move CB-183,315 into Phase 3 trial for treatment of CDAD

Cubist Pharmaceuticals, Inc. today announced it plans to move CB-183,315, being studied for the treatment of a severe and sometimes life-threatening diarrhea caused by Clostridium difficile known as C. difficile-associated diarrhea, or CDAD, into late-stage trials.

29 Sep 2011

Anthrax defenses need to be strengthened: Experts

It has been a decade since the anthrax attacks brought home the reality of bioterrorism and the nation now has a stockpile of some basic tools to fight back against a few of the threats that worry defense experts the most.

28 Sep 2011

Asthma patients admitted to hospital with H1N1 are half as likely to die from infection

People with asthma who are admitted to hospital with pandemic influenza H1N1 (swine flu) are half as likely to die or require intensive care than those without asthma, according to new research.

26 Sep 2011

Vaxent, PREVENT sign license agreement to develop and commercialize Strep-A vaccine

An international collaboration between Vaxent, a Memphis-based early stage vaccine development company in the Memphis Bioworks Foundation Incubator, and The Pan-Provincial Vaccine Enterprise Inc. (PREVENT), a Centre of Excellence for Commercialization and Research (CECR) in Saskatchewan, has put a vaccine for group A streptococcus (Strep-A) back on the path for potential commercialization.

26 Sep 2011

Scientists identify genetic variants associated with lung health

Scientists have for the first time discovered sixteen new sections of the genetic code that relate to lung health -- opening up the possibility for better prevention as well as treatment for lung diseases.

26 Sep 2011

New treatment concept for complex malaria

Team from the Medical University of Vienna, led by Harald Noedl from the Institute of Specific Prophylaxis and Tropical Medicine, is developing a new treatment concept for complex malaria in Bangladesh. This treatment is intended to significantly cut the mortality rate and could save the lives of tens of thousands of children.

23 Sep 2011

EMA CHMP adopts positive opinion for DIFICLIR to treat C. difficile infection

Astellas Pharma Europe Ltd. (APEL) and Optimer Pharmaceuticals, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for DIFICLIR (fidaxomicin) tablets for the treatment of adults suffering with a Clostridium difficile infection (CDI), also known as C. difficile-associated diarrhoea (CDAD).

23 Sep 2011

Two TGen students receive SRP grants for antibiotic resistance and Alzheimer's research

Two Arizona university graduate students working at the Translational Genomics Research Institute (TGen) have each received $50,000 grants from the Salt River Project.

23 Sep 2011

'ResistanceMap' tracks antibiotic resistance online

"Extending the Cure," a research project of the Center for Disease Dynamics, Economics & Policy that looks at antibiotic resistance, on Wednesday launched a map "designed to be a tool for public health, researchers, doctors, the media and the public to track resistant pathogens, which is a growing problem around the world," the Washington Post's "The Checkup" blog reports.

22 Sep 2011

Aradigm announces two ciprofloxacin Phase 2b study data on non-CF bronchiectasis

Aradigm Corporation today announced it is presenting data on September 26, 2011, from its Phase 2b studies at the ERS Annual Congress in Amsterdam, Netherlands. The two podium presentations review the results from the Company's two clinical trials of inhaled ciprofloxacin in non-cystic fibrosis bronchiectasis (BE) patients.

22 Sep 2011

NIH to honor IGB faculty member with innovator award

Douglas A. Mitchell, IGB faculty member in the Mining Microbial Genomes for Novel Antibiotics research theme and assistant professor in the Department of Chemistry, is a recipient of the 2011 National Institutes of Health Director's New Innovator Award. The award recognizes bold ideas from some of the nation's most promising new scientists.

22 Sep 2011

ASU scientists receive USDA grants to combat food-related illness

Roughly 1 in six Americans are sickened every year by food-borne ailments, according to the Centers for Disease Control and Prevention. The effects of these illnesses range from acutely unpleasant to lethal, and the problem may be getting worse, as our food supply becomes more global, with an increasing number of antibiotic-resistant pathogens.

21 Sep 2011

Antivirals from shark cartilage compound squalamine

A unique compound originally isolated from sharks could prove to be a promising treatment for hepatitis B and C and other viral diseases, researchers say. Known as squalamine, the drug has not yet been tested as an antiviral agent in humans, but it has been given to hundreds of people enrolled in clinical trials designed to test its usefulness for other conditions. Researchers say they hope to begin human trials to test the compound’s antiviral activity within the next year.

21 Sep 2011

A code beyond DNA: Modified tRNA bases are characteristic of species

Our genetic code consists of four “letters” in the form of the nucleobases in our DNA and RNA. Three letters together form a “word” that are translated into an amino acid by tRNA and combined into proteins. Special markings subdivide the gene into active and inactive regions. A third possible level of information has so far received less attention: the chemical modification of tRNA nucleobases. In the journal Angewandte Chemie Thomas Carell and a team at the University of Munich have now demonstrated that tRNA modification profiles can be used for the characterization of species and the differentiation of pathogenic and nonpathogenic bacterial strains.

20 Sep 2011